Arrowhead Pharmaceuticals - Latest News and Information
ARWR
Arrowhead Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and delivering RNA interference (RNAi)–based therapies across multiple disease areas, including cardiometabolic and inflammatory pulmonary diseases. Its TRiM platform targets genes to silence disease-causing pathways, with programs addressing conditions such as severe hypertriglyceridemia, dyslipidemia, and various cardiovascular and lung diseases. The company operates globally with research and development activities and clinical trials in several countries, including the United States, Australia, Canada, and Europe.
Arrowhead siRNA Data in Obesity Mark POC for Adipose Delivery
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
2025 Novel Large Molecule FDA Drug Approvals
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
No recent deals for this company.
